Company intelligence / Profile preview

Contineum Therapeutics

San Diego, California, United Statescontineum-tx.com ↗

Ownership: Public · CTNM
Employees: ~41
Development stage: Phase 2

Overview

Contineum Therapeutics has multiple drug candidates in clinical trials. PIPE-791 targets LPA1 for IPF, PrMS, and chronic pain. PIPE-307 targets the M1 receptor for RRMS and major depressive disorder and is in Phase 2 clinical trials. CTX-343 is a peripherally restricted LPA1R antagonist also under development[1][3][4]. No pivotal trial results or commercial products reported as of May 2025.

Therapeutic areas: PulmonologyPsychiatryNeurology
Modalities: small molecules
Industry: Biotech

Drug pipeline

7 assets

PIPE-791

6 more assets in the full pipeline.

Request access →

Financials

Market cap: $551.5M
Total revenue: $0
Enterprise value: $321.5M

Beyond the preview

Go deeper on Contineum Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Contineum Therapeutics.

Explore the full profile